Methodology
How we score evidence depth, source recency and safety clarity. Behind-the-scenes editorial decisions. The reasoning, not just the result.
No articles in this category yet.
Browse other coverage
Latest from the blog
Retatrutide in Sweden: no approval yet
Retatrutide holds no EMA or Läkemedelsverket authorisation as of July 2026. Here is where the TRIUMPH trials stand and what that means for Swedish patients.
Semax in Sweden: regulatory status
Semax has no marketing authorisation in Sweden or the EU. Here is the Läkemedelslagen framework, what changed in 2025-2026, and who to ask.
Tesamorelin vs CJC-1295 with Ipamorelin
Both stacks pair a GHRH analog with ipamorelin, but tesamorelin and CJC-1295 have different half-lives and very different evidence bases.
Semaglutide in Pakistan: real-world data
A 30-week Pakistan study reports HbA1c reductions of 1.86 points and 7.84 kg mean weight loss with semaglutide in routine outpatient care.
Crunchometer: open-source feeding analysis
An open-source acoustic device for mice detects semaglutide appetite suppression and maps meal-tracking neurons in the lateral hypothalamus.
GLP-1 vs oral agents: insulin stop in T2D
A 2026 Annals study found GLP-1 agonists did not raise insulin discontinuation rates above SGLT-2 or DPP-4 inhibitors in 8,869 veterans with type 2 diabetes.